Oct 30, 2025 • Zacks Commentary
NEUTRAL
New Strong Sell Stocks for Oct. 30th
EQX, GDEN and KNSA have been added to the Zacks Rank #5 (Strong Sell) List on October 30, 2025.
Oct 28, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Kiniksa Pharmaceuticals International, plc ( KNSA ) Q3 Earnings Miss Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of -30.30% and +8.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 28, 2025 • GlobeNewswire
NEUTRAL
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
- ARCALYST® ( rilonacept ) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387 granted Orphan Drug Designation for the treatment of pericarditis - - Cash balance increased by ...
Oct 17, 2025 • GlobeNewswire
NEUTRAL
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
LONDON, Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Kiniksa Pharmaceuticals International, plc ( Nasdaq: KNSA ) ( Kiniksa ) , a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S.
Oct 16, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Why Kiniksa Pharmaceuticals International, plc ( KNSA ) is Poised to Beat Earnings Estimates Again
Kiniksa Pharmaceuticals International, plc (KNSA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Oct 14, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc ( KNSA ) Could Surge 29.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the ...